NASDAQ:DAWN Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free DAWN Stock Alerts $16.00 -0.38 (-2.32%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$15.92▼$16.6650-Day Range$13.21▼$17.6952-Week Range$9.67▼$18.07Volume734,954 shsAverage Volume883,982 shsMarket Capitalization$1.40 billionP/E RatioN/ADividend YieldN/APrice Target$37.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Day One Biopharmaceuticals alerts: Email Address Day One Biopharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside135.4% Upside$37.67 Price TargetShort InterestBearish18.47% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.02Based on 42 Articles This WeekInsider TradingSelling Shares$3.38 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.67) to ($2.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.76 out of 5 starsMedical Sector418th out of 921 stocksPharmaceutical Preparations Industry188th out of 428 stocks 4.4 Analyst's Opinion Consensus RatingDay One Biopharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDay One Biopharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Day One Biopharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted18.47% of the float of Day One Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDay One Biopharmaceuticals has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in Day One Biopharmaceuticals has recently increased by 25.17%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDay One Biopharmaceuticals does not currently pay a dividend.Dividend GrowthDay One Biopharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DAWN. Previous Next 2.8 News and Social Media Coverage News SentimentDay One Biopharmaceuticals has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 42 news articles for Day One Biopharmaceuticals this week, compared to 3 articles on an average week.Search Interest14 people have searched for DAWN on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat Follows6 people have added Day One Biopharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Day One Biopharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,376,817.00 in company stock.Percentage Held by InsidersOnly 8.40% of the stock of Day One Biopharmaceuticals is held by insiders.Percentage Held by Institutions87.95% of the stock of Day One Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Day One Biopharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Day One Biopharmaceuticals are expected to grow in the coming year, from ($2.67) to ($2.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Day One Biopharmaceuticals is -6.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Day One Biopharmaceuticals is -6.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDay One Biopharmaceuticals has a P/B Ratio of 4.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Day One Biopharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Day One Biopharmaceuticals Stock (NASDAQ:DAWN)Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Read More DAWN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DAWN Stock News HeadlinesMay 4, 2024 | insidertrades.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II Sells 8,078 SharesApril 23, 2024 | insidertrades.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 10,000 SharesMay 10, 2024 | Stansberry Research (Ad)Biggest hedge fund manager has huge warning for U.S. dollarPrescient CEO Makes Shocking New Prediction Known for his eerily accurate market calls over the years, this CEO has just revealed his newest prediction about "America's New Money."May 10, 2024 | americanbankingnews.comFY2027 EPS Estimates for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Decreased by AnalystMay 10, 2024 | americanbankingnews.comDay One Biopharmaceuticals, Inc. to Post Q3 2024 Earnings of ($0.69) Per Share, HC Wainwright Forecasts (NASDAQ:DAWN)May 10, 2024 | americanbankingnews.comCapital One Financial Comments on Day One Biopharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:DAWN)May 8, 2024 | americanbankingnews.comDay One Biopharmaceuticals (NASDAQ:DAWN) Given "Outperform" Rating at WedbushMay 8, 2024 | americanbankingnews.comDay One Biopharmaceuticals (NASDAQ:DAWN) Given "Buy" Rating at Needham & Company LLCMay 10, 2024 | Stansberry Research (Ad)Biggest hedge fund manager has huge warning for U.S. dollarPrescient CEO Makes Shocking New Prediction Known for his eerily accurate market calls over the years, this CEO has just revealed his newest prediction about "America's New Money."May 8, 2024 | americanbankingnews.comDay One Biopharmaceuticals (NASDAQ:DAWN) Given New $40.00 Price Target at HC WainwrightMay 8, 2024 | markets.businessinsider.comBuy Rating for Day One Biopharmaceuticals Amidst DAY101 Approval and Strong Market EntryMay 8, 2024 | markets.businessinsider.comBuy Rating on Day One Biopharmaceuticals: Ojemda’s Market Potential and Strategic CommercializationMay 7, 2024 | finanznachrichten.deDay One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2024 Financial Results and Corporate ProgressMay 7, 2024 | msn.comIndegene IPO subscribed 7.34 times on Day 2May 7, 2024 | americanbankingnews.comDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down Following Insider SellingMay 6, 2024 | globenewswire.comDay One Reports First Quarter 2024 Financial Results and Corporate ProgressMay 5, 2024 | americanbankingnews.comJeremy Bender Sells 9,154 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) StockMay 5, 2024 | americanbankingnews.comCharles N. York II Sells 8,078 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) StockMay 5, 2024 | americanbankingnews.comCharles N. York II Sells 52,183 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) StockMay 5, 2024 | americanbankingnews.comJeremy Bender Sells 70,051 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) StockMay 4, 2024 | finance.yahoo.comInsider Sale at Day One Biopharmaceuticals Inc (DAWN)April 24, 2024 | msn.comDay One slips despite Ojemda approval as BofA says label “not a home run”April 24, 2024 | seekingalpha.comDay One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation FairApril 23, 2024 | markets.businessinsider.comBuy Rating on Day One Biopharmaceuticals Amid FDA Approval and Strong Market ProspectsApril 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Day One Biopharmaceuticals Following FDA Approval of OjemdaApril 23, 2024 | finance.yahoo.comDay One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain TumorApril 23, 2024 | globenewswire.comDay One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain TumorSee More Headlines Receive DAWN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today5/10/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DAWN CUSIPN/A CIK1845337 Webdayonebio.com Phone650-484-0899FaxN/AEmployees155Year FoundedN/APrice Target and Rating Average Stock Price Target$37.67 High Stock Price Target$44.00 Low Stock Price Target$33.00 Potential Upside/Downside+130.9%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-188,920,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-51.67% Return on Assets-48.30% Debt Debt-to-Equity RatioN/A Current Ratio12.72 Quick Ratio12.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.98 per share Price / Book4.10Miscellaneous Outstanding Shares87,380,000Free Float80,037,000Market Cap$1.43 billion OptionableOptionable Beta-1.44 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Jeremy Bender M.B.A. (Age 53)Ph.D., CEO, President & Director Comp: $900kDr. Samuel C. Blackman M.D. (Age 55)Ph.D., Co-Founder and Head of R&D Comp: $651kMr. Charles N. York II (Age 47)COO, CFO & Secretary Comp: $715kDr. Mike Preigh Ph.D.Chief of Technology OperationsMr. Adam Dubow (Age 57)General Counsel Ms. Jaa RobersonChief People OfficerDr. Davy Chiodin Ph.D.Pharm.D., Chief Development OfficerMs. Lauren Merendino M.B.A. (Age 48)Chief Commercial Officer Dr. Elly Barry M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsXencorNASDAQ:XNCRMorphicNASDAQ:MORFProtagonist TherapeuticsNASDAQ:PTGXAkero TherapeuticsNASDAQ:AKRODynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsState Board of Administration of Florida Retirement SystemSold 7,230 shares on 5/9/2024Ownership: 0.012%Summit Rock Advisors LPBought 51,502 shares on 5/8/2024Ownership: 0.059%ProShare Advisors LLCBought 1,447 shares on 5/8/2024Ownership: 0.020%TimesSquare Capital Management LLCSold 30,920 shares on 5/7/2024Ownership: 1.871%Regency Capital Management Inc. DESold 1,000 shares on 5/7/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions DAWN Stock Analysis - Frequently Asked Questions Should I buy or sell Day One Biopharmaceuticals stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Day One Biopharmaceuticals in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DAWN shares. View DAWN analyst ratings or view top-rated stocks. What is Day One Biopharmaceuticals' stock price target for 2024? 7 analysts have issued 1-year price targets for Day One Biopharmaceuticals' stock. Their DAWN share price targets range from $33.00 to $44.00. On average, they predict the company's stock price to reach $37.67 in the next twelve months. This suggests a possible upside of 135.4% from the stock's current price. View analysts price targets for DAWN or view top-rated stocks among Wall Street analysts. How have DAWN shares performed in 2024? Day One Biopharmaceuticals' stock was trading at $14.60 at the beginning of the year. Since then, DAWN shares have increased by 9.6% and is now trading at $16.00. View the best growth stocks for 2024 here. When is Day One Biopharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our DAWN earnings forecast. How were Day One Biopharmaceuticals' earnings last quarter? Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) released its quarterly earnings results on Monday, February, 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by $0.07. What ETFs hold Day One Biopharmaceuticals' stock? ETFs with the largest weight of Day One Biopharmaceuticals (NASDAQ:DAWN) stock in their portfolio include Tema Oncology ETF (CANC), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ALPS Medical Breakthroughs ETF (SBIO).iShares Micro-Cap ETF (IWC). When did Day One Biopharmaceuticals IPO? Day One Biopharmaceuticals (DAWN) raised $126 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,400,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Day One Biopharmaceuticals' major shareholders? Day One Biopharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Atlas Venture Life Science Advisors LLC (7.36%), TimesSquare Capital Management LLC (1.87%), Hennion & Walsh Asset Management Inc. (0.07%), Summit Rock Advisors LP (0.06%), Mirae Asset Global Investments Co. Ltd. (0.03%) and ProShare Advisors LLC (0.02%). Insiders that own company stock include Adam Dubow, Ai Day1 Llc, Charles N York II, Jeremy Bender, Julie Papanek Grant, Michael Gladstone, Papanek Julie Grant, Pharmaceutical Co Ltd Takeda, Samuel C Blackman, Venture Fund Xi LP Atlas and Xi LP Canaan. View institutional ownership trends. How do I buy shares of Day One Biopharmaceuticals? Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DAWN) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeHe Is Giving Away BitcoinCrypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingMissed NVDA? Buy this AI stock NOWChaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable ProsperityYou need to know these two things about AI stocks ASAP…InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
